Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation

By sjmartinez • February 9, 2024

abatacept, acitretin, adalimumab, apremilast, biologics, brodalumab, certolizumab, cyclosporine, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, vaccination, vaccines,

Tags: abatacept, acitretin, adalimumab, apremilast, Biologics, brodalumab, certolizumab, cyclosporine, Dermatology, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, Publications, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, Vaccination, vaccines

Moyamoya disease presenting as galactorrhea

Noveir SD, Agrawal N. Moyamoya disease presenting as galactorrhea. JCEM Case Rep. 2026 Oct 13;4(11):luag296. doi: 10.1210/jcemcr/luag296. PMID: 42871260; PMCID: PMC13658269.

Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns

Park I, Bayrouti A, MacIntyre D, Le V, Nguyen KB. Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns. Dermatol[...]

Closing the Gap: The Ethics of Non-Physician Delegation in Mohs Reconstruction

Li R, Ramirez Y, Stone L, Klufas T, Zhou AE, Tucci C, Beynet DP, Lo Sicco K, Grant-Kels JM. Closing the Gap: The Ethics of[...]